{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=50", "query": { "intervention": "Induction Phase", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 2300, "total_pages": 230, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T04:55:19.820Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07227584", "title": "ALL Backbone in AYAs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Philadelphia Chromosome-Negative Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia (ALL)", "Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Oncaspar", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "ALL", "summary": "18 Years to 51 Years" }, "enrollment_count": 67, "start_date": "2026-04-03", "completion_date": "2035-07-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227584" }, { "nct_id": "NCT00005793", "title": "A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "16 Years to 59 Years" }, "enrollment_count": 41, "start_date": "1999-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2012-09-25", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005793" }, { "nct_id": "NCT03395184", "title": "Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "PF-06651600 Placebo", "type": "DRUG" }, { "name": "PF-06651600", "type": "DRUG" }, { "name": "Placebo PF-06700841", "type": "DRUG" }, { "name": "PF-06700841", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 244, "start_date": "2018-02-02", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 57, "location_summary": "Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395184" }, { "nct_id": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small-Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2021-11-18", "completion_date": "2028-02-28", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 12, "location_summary": "Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 9 more", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091567" }, { "nct_id": "NCT03113500", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult T-Cell Leukemia/Lymphoma", "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Angioimmunoblastic T-Cell Lymphoma", "Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Hepatosplenic T-Cell Lymphoma", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-05-25", "completion_date": "2027-04-25", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 4, "location_summary": "Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113500" }, { "nct_id": "NCT05336409", "title": "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "R/R CD19-Positive B-Cell Malignancies", "Indolent Non-Hodgkin Lymphoma", "Aggressive Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "CNTY-101", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Century Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-01-24", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Diego, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05336409" }, { "nct_id": "NCT03609593", "title": "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicole Lamanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 42, "start_date": "2018-11-12", "completion_date": "2026-01-27", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03609593" }, { "nct_id": "NCT06952504", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1123, "start_date": "2025-05-22", "completion_date": "2032-05-24", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 53, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Solvang", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952504" }, { "nct_id": "NCT02513459", "title": "A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Risankizumab 600 mg IV", "type": "DRUG" }, { "name": "Risankizumab 180 mg SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 65, "start_date": "2015-09-16", "completion_date": "2019-06-19", "has_results": true, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 2, "location_summary": "Chevy Chase, Maryland • Chesterfield, Michigan", "locations": [ { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Chesterfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02513459" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-31T04:55:19.820Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" } ] }